Global Registry Could Help Solve Asia’s Diabetes Crisis
Asia’s socioeconomic growth and increased population longevity is causing an epidemiological shift in the health issues and health care challenges. Historically, infectious diseases have attracted the most attention and research dollars, but the region is now seeing a rise in chronic disorders previously more common in Western nations, including heart disease and diabetes. Diabetes is one area that a registry approach may pay dividends.
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”